Indivior announced its Q3 2026 results and confirmed the imminent closing of its all-stock merger with Supernus Pharmaceuticals on November 2, 2026. The combined entity will operate as Supernus, Inc. and trade under the ticker 'SUPN' on the Nasdaq Global Select Market starting November 3, 2026, marking a significant corporate restructuring for both companies.
Indivior's 8-K filing confirms the final stages of its merger with Supernus Pharmaceuticals, a major corporate event. This all-stock transaction will result in Indivior ceasing to exist as a separate trading entity, with the combined company operating under the Supernus name and ticker 'SUPN'. This is highly significant for shareholders of both companies, as Indivior shareholders will receive Supernus stock, and Supernus will become a larger, more diversified CNS-focused biopharmaceutical company. Short-term, this could lead to volatility as investors adjust to the new entity and its combined financials. Long-term, the success of the merger hinges on effective integration and the realization of anticipated synergies, offering a key opportunity for traders to evaluate the new 'SUPN' as a consolidated biopharma player.